

Table 3. The characteristics of the patients (n= 18) that followed the fenofibrate treatment at baseline, at 1 month and at 3 months

	Baseline	1 month	3 months
Age (years)	53± 13		
Gender (males/ females)	(8/10)		
BMI(Kg/m ²)	36.6±8.7	36.0±8.9 ^a	35.0±9.1 ^{b,c}
TC (mg/dL)	255±42	222±33 ^a	227±37 ^b
TRG (mg/dL)	295 (144-400)	139 (105-383) ^a	142 (89-368) ^b
HDL-C (mg/dL)	44±7	47±8	48±7
LDL-C (mg/dL)	142±28	120±22 ^a	125±21 ^b
ApoA-I (mg/dL)	140.6±14.1	144.2±22.3	148.4±16.9
HOMA-index	4.6±4.3	3.5±1.6	2.7±1.5 ^c
Total adiponectin (mg/L)	5.0±2.7	4.7±2.3	4.1±1.4
HMW adiponectin (mg/L)	2.4±1.1	2.4±1.2	2.2±0.9
HMW-to-total adiponectin ratio	0.52±0.20	0.53±0.20	0.54±0.20

Data are means ± SD for normally distributed variables or median (range) for non-normal variables.

BMI: body mass index; TC: total cholesterol; TRG: triglycerides; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; ApoA-I: apolipoprotein A-I; HOMA index: homeostasis model assessment insulin resistance-index.

^ap <0.050 for 1 month vs baseline; ^bp <0.050 for 3 months vs baseline; ^cp <0.050 for 3 months vs 1 month.